388 related articles for article (PubMed ID: 33160642)
21. Current status of immunotherapy for advanced gastric cancer.
Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy for the treatment of colorectal cancer.
Lumish MA; Cercek A
J Surg Oncol; 2021 Mar; 123(3):760-774. PubMed ID: 33595891
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
24. Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies.
Katz H; Biglow L; Alsharedi M
J Gastrointest Cancer; 2020 Jun; 51(2):611-619. PubMed ID: 31028537
[TBL] [Abstract][Full Text] [Related]
25. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
[TBL] [Abstract][Full Text] [Related]
26. Prospect of immunotherapy in neoadjuvant/adjuvant treatment for early breast cancer.
Miyashita M; Ishida T
Chin Clin Oncol; 2020 Jun; 9(3):28. PubMed ID: 32312056
[TBL] [Abstract][Full Text] [Related]
27. Results and challenges of immune checkpoint inhibitors in colorectal cancer.
Emambux S; Tachon G; Junca A; Tougeron D
Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676
[TBL] [Abstract][Full Text] [Related]
28. Next generation of immune checkpoint inhibitors and beyond.
Marin-Acevedo JA; Kimbrough EO; Lou Y
J Hematol Oncol; 2021 Mar; 14(1):45. PubMed ID: 33741032
[TBL] [Abstract][Full Text] [Related]
29. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
[TBL] [Abstract][Full Text] [Related]
30. Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers.
Wang L; Qu J; Zhou N; Hou H; Jiang M; Zhang X
Biomed Pharmacother; 2020 Oct; 130():110626. PubMed ID: 32791396
[TBL] [Abstract][Full Text] [Related]
31. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Bellmunt J; Powles T; Vogelzang NJ
Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
[TBL] [Abstract][Full Text] [Related]
32. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma.
Powles T; Walker J; Andrew Williams J; Bellmunt J
Cancer Treat Rev; 2020 Jan; 82():101925. PubMed ID: 31785413
[TBL] [Abstract][Full Text] [Related]
33. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
Li K; Tian H
J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
[TBL] [Abstract][Full Text] [Related]
34. Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.
Lanka SM; Zorko NA; Antonarakis ES; Barata PC
Curr Oncol; 2023 Apr; 30(4):4246-4256. PubMed ID: 37185436
[TBL] [Abstract][Full Text] [Related]
35. Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects.
Banday AH; Abdalla M
Curr Med Chem; 2023; 30(28):3215-3237. PubMed ID: 35986535
[TBL] [Abstract][Full Text] [Related]
36. [MSI Metastatic solid tumors treatment and immunotherapies].
Bouchez C; Kempf E; Tournigand C
Bull Cancer; 2019 Feb; 106(2):143-150. PubMed ID: 30737018
[TBL] [Abstract][Full Text] [Related]
37. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
38. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
39. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zacharis A; Grüllich C
Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
[TBL] [Abstract][Full Text] [Related]
40.
Li M; Ma Y; Zhong Y; Liu Q; Chen C; Qiang L; Wang X
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]